REPROCELL Europe wins CV Technology Innovator Awards 2016 for Alvetex
16 September 2016
REPROCELL Europe has won the Corporate Vision Technology Innovation Award 2016 for Alvetex technology for 3D cell culture.
Prof Stefan Przyborski speaking at BBS 2016 Biennial Meeting
06 July 2016
ReproCELL Europe Ltd’s Chief Scientific Officer Prof Stefan Przyborski is giving a public lecture on “Scaffold Cell Culture Technology for Generation of In Vivo-like Tissue Models” at the British Biophysical Society 2016 Biennial Meeting 6th-8th July, University of Liverpool, Liverpool, UK.
REPROCELL Europe’s (formerly Reinnervate’s) CSO Prof Stefan Przyborski to give an Alvetex Seminar at the University of Oxford, 24 May 2016
20 May 2016
Professor Stefan Przyborski, Chief Scientific Officer of REPROCELL Europe (formerly Reinnervate), is to give a seminar on Alvetex next week, 24th May 2016.
Latest Proteon and Biopta publication demonstrates Proteon's Vonapanitase effects in human cephalic veins
13 May 2016
Proteon Therapeutics Announces Publication in Cardiovascular Pharmacology: Open Access Describing Promising Nonclinical Results for Vonapanitase in Improving Arteriovenous Fistula (AVF) Maturation and patency in Chronic Kidney Disease (CKD) Patients.
Proteon and Biopta publication shows promising nonclinical results on Proteon's Vonapanitase
21 April 2016
Proteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery Disease.
Reinnervate Ltd wins Corporate Vision’s 2015 Technology Innovator Award for Alvetex
22 March 2016
We are pleased to announce that Reinnervate Ltd has been awarded Corporate Vision’s 2015 Technology Innovator Award for Alvetex 3D cell culture. Alvetex has been awarded the title, “Most Advanced 3D Cell Technology.”
Alvetex in Space
14 January 2016
While the first British ESA astronaut Tim Peake is currently on the International Space Station (ISS) and is about to make his first spacewalk, now is a good time to mention again that Reinnervate’s flagship product, Alvetex® Scaffold, has been used as part of a BBSRC-funded project on the ISS in recent months.
REPROCELL acquires Biopta to expand its drug discovery services
25 November 2015
The Japanese regenerative medicine company REPROCELL Inc. has announced the acquisition of the Scottish life sciences company, Biopta.
Biopta co-authors research in the European Respiratory Journal
18 November 2015
The impact of fresh human tissue studies for translational work performed at Biopta has once again been demonstrated with this latest publication at the European Respiratory Society.
Publication of Paper on “3D culture model construction of mouse neurons” in Neuroscience Letters
18 November 2015
Reinnervate (now REPROCELL Europe) has written a paper on the topic of “3D culture model construction of mouse neurons”, along with other contributors including Durham University (UK), that has recently been published in ‘Neuroscience Letters’.
A Joint Development with the National Cancer Center Information Regarding the Sale of “ReproHP Medium,” a Culture Fluid for Human Primary Liver Cells with High Levels of Functionality
16 November 2015
“ReproHP Medium,” a highly functional culture fluid for human primary liver cells developed in conjunction with the National Cancer Center, is set to go on sale in December this year.
Notice of Passage of Examination for United States Patent Application Concerning Amplification Method of Hematopoietic Stem Cells
04 November 2015
REPROCELL like to inform you that a patent application concerning an amplification method of hematopoietic stem cells which we applied for jointly with Nissan Chemical Industries, Ltd., has passed screening in the United States.
REPROCELL announces publication of a research report on “3D Skin Model Construction,” submitted to the International Scientific Journal “Molecular Cancer Therapeutics” by REPROCELL and others
19 October 2015
Read more about REPROCELL CSO Professor Stefan Przyborski's latest publication on 3D Skin Model Construction published in Molecular Cancer Therapeutics
The REPROCELL Group announces publication of a paper on its state-of-the-art RNA Reprogramming technology in Human Gene Therapy, an international journal
14 October 2015
Group affiliate Stemgent Inc. (US) is pleased to announce the publication of a paper on state-of-the-art iPS cell production technology, entitled “RNA Reprogramming,” that was written collaboratively with the Whitehead Institute (USA).
REPROCELL concludes license agreement with Keio University for the exclusive sale of myocardial cells derived from disease-type (long QT syndrome, a congenital heart disease) iPS cells
08 September 2015
REPROCELL is pleased to announce that our company has entered into an exclusive licensing agreement with Keio University regarding myocardial cells derived from disease-type (long QT syndrome, a congenital heart disease) iPS cells.
Announcement: New High Performance Cryopreservation Solution – ReproCryo DMSO Free
26 August 2015
Read more about how REPROCELL's new high-performance cryopreservation solution ReproCryo (DMSO free) is advancing the field of regenerative medicine.
Announcement of Award for Prototype Development of Large-Scale Production on Human-iPSC derived Cardiomyocytes
14 August 2015
REPROCELL would like to announce that on August 3rd, 2015, one of our projects, “Prototype Development of a Large- Scale Production Mechanism of Highly Functional Cardiomyocytes Derived From Human iPS Cells” (hereafter, “the project”) was selected to receive a Subsidy for Collaborative Projects to Advance the Creation of an Innovative Manufacturing Industry (FY 2015-2016).
Diseased neurons derived from iPS cells of Alzheimer’s disease patients Initiation of sales of “ReproNeuro AD-patient”
29 July 2015
REPROCELL is pleased to announce that on August 10th our company began sales of “ReproNeuro AD-patient,” diseased neurons made from iPS cells derived from Alzheimer’s disease patients.
Announcement: sales commencement of “ReproNeuro MQ Medium”, a cell culture kit which enables the creation of high-functioning nerve cells derived from human iPS cells
21 July 2015
This is a notice that we will on August 3rd 2015 commence sales of “ReproNeuro MQ Medium”, a cell culture kit which enables the creation of high-functioning nerve cells derived from human iPS cells.
Announcement of Award for Prototype Development of a Liver Cell Kit
01 July 2015
REPROCELL is pleased to announce that one of our projects, “Prototype Development of a Liver Cell Kit Derived From Functional Human Induced Pluripotent Stem (iPS) Cells for Applications in Drug Discovery” has been selected as a recipient of Grant for Manufacturing, Commerce, and Service Innovation additionally allocated for FY 2014-2015.